Immunomodulating Agents as Antipruritics.

  title={Immunomodulating Agents as Antipruritics.},
  author={Stephen P. Erickson and Zachary P. Nahmias and Ilana S. Rosman and Brian S. Kim},
  journal={Dermatologic clinics},
  volume={36 3},

Immunotargets and Therapy for Prurigo Nodularis

This review will highlight targets of the immune cascade and explore current immunomodulating treatments as well as immunotherapies on the horizon for the management of prurigo nodularis.

Clinical Review: Pruritus in Allergy and Immunology

How recent advances in itch biology have provided critical new insight into a variety of novel therapeutic avenues for chronic itch in the setting of a number of allergic disorders will likely inform the problem of pruritus in a range of well-established and emerging conditions in the field of allergy is highlighted.

Pruritus in allergy and immunology.

Therapeutic potential of biologics in prurigo nodularis

The off-label advent of dupilumab offered advanced insight into the pathogenesis of CNPG and showed an impressive relief of pruritus in the vast majority of patients.

Innate Immune Regulation of Dermatitis.

Biologics in dermatology: What does the future hold?

  • C. Yavuz
  • Medicine, Biology
    Dermatologic therapy
  • 2019
As the first dermatological biological treatment, infliximab was first used in the treatment of psoriasis in 2001 and the concept has emerged of treatment directed to a patient‐specific target.

The Neuroimmune Axis in Skin Sensation, Inflammation, and Immunity

By focusing on itch biology and how it has been informed by the more established field of pain research, this work highlights recent interdisciplinary studies that demonstrate how novel neuroimmune interactions underlie a diversity of sensory, inflammatory, and infectious diseases.

Management of Itch in the Elderly: A Review

Management in the elderly may be complicated by differential pharmacokinetics of medications, the presence of co-morbid health conditions, cognitive disorders, physical limitations, and polypharmacy.

MRGPRX2 signals its importance in cutaneous mast cell biology: Does MRGPRX2 connect mast cells and atopic dermatitis?

The hypothesis is developed that MRGPRX2 constitutes the missing link connecting MCs and AD, at least in selected endotypes, and support comes from the multifold changes in the MC‐neuronal system of AD skin.



Current and Emerging Therapies for Itch Management in Psoriasis

While there remains a need for treatments that specifically target psoriatic itch, newly licensed therapies including secukinumab, ixekizumab and apremilast have been shown to rapidly and effectively mediate itch reduction.

Pruritus in allergy and immunology.

Pathogenic Intracellular and Autoimmune Mechanisms in Urticaria and Angioedema

As the understanding of the pathogenesis of idiopathic urticaria increases, development of additional drugs targeting these pathways may provide relief for the significant physical and psychological morbidity experienced by patients with this disorder.

Omalizumab for the treatment of chronic idiopathic or spontaneous urticaria.

Omalizumab diminished clinical symptoms and signs of chronic idiopathic urticaria in patients who had remained symptomatic despite the use of approved doses of H-antihistamine therapy (licensed doses).

Mediators of Chronic Pruritus in Atopic Dermatitis: Getting the Itch Out?

This review will focus on the mediators of chronic pruritus mainly associated with atopic dermatitis (atopic itch), as well as numerous different therapeutic options.

Usefulness of a short course of oral prednisone in antihistamine-resistant chronic urticaria: a retrospective analysis.

A single short course of prednisone induced remission in nearly 50% of patients with antihistamine-resistant chronic urticaria, and a second courseinduced remission in a further 9%.

Antihistamines and itch.

It has now been shown that a selective H₄R antagonist can inhibit histamine-induced itch in humans, which points to the therapeutic potential of H‽R antagonists for the treatment of pruritus not controlled by antihistamines that target the H⁁R.

Onset of pruritus relief with pimecrolimus cream 1% in adult patients with atopic dermatitis: a randomized trial

Pimecrolimus cream 1% effectively improves/relieves pruritus associated with atopic dermatitis (AD) and in adults with mild/moderate AD and moderate/severe Pruritus, and the timing of relief was investigated.

Treatment of refractory prurigo nodularis with lenalidomide.

Prurigo nodularis is an intensely pruritic disorder in which chronic scratching and rubbing lead to the formation of eroded and excoriated skin nodules that may become generalized. Therapy for

Pathology and classification of urticaria.

  • M. Greaves
  • Medicine, Biology
    Immunology and allergy clinics of North America
  • 2014